The FDA has approved the drug Epclusa to treat adult patients with chronic Hep C both with and without cirrhosis.
his presentation includes tips from providers experienced with advocating successfully for hepatitis C medication coverage for their patients.
Presentation | Small hospital improves screening and implements reflex testing HepCX Champion and Director of Ambulatory Services of Kingsbrook Jewish Medical Center, Dr. Neil Pasco, presented at the June 2nd champion’s meeting. Dr. Pasco described the current state of hep C ca...
The NYS Drug Utilization Review Board voted to eliminate most restrictions on prescribing hepatitis C medications for all Medicaid fee-for-service patients.
To determine the impact of the NYS Hepatitis C Testing Law, the NYSDOH drew from multiple data sources that assessed testing levels in New York before and after the law went into effect.
VOCAL-NY and community leaders will attend the meeting to advocate for unrestricted access to Hepatitis C drug coverage.
The purpose of Hep C directory is to provide the public and other providers with a listing of hepatitis C care and treatment providers within New York State.
FDA Expands Daklinza/Sovaldi Approval to Include Treatment of Hep C Genotype 1
The Health Department today released a new report detailing the city’s hepatitis B and C surveillance, research, and programmatic activities in 2014.
The U.S. Food and Drug Administration has approved Zepatier with or without ribavirin for the treatment of chronic Hepatitis C genotypes 1 and 4 infections in adult patients.
